Kirjaudu sisään Inderes Free -tilillesi nähdäksesi kaikki sivun maksuton sisältö.
Luo ilmainen tunnus

I-tech

63,00 SEK

−2,78%

Alle 1K seuraajaa

ITECH

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

−2,78 %
+15,17 %
+42,53 %
+20,69 %
−1,25 %
−35,71 %
+72,13 %
−14,40 %
+155,42 %

I-tech operates in marine technology. The company conducts research and development of substances that inhibit marine fouling on ship hulls. In addition, the products can be used for various marine installations in fish farming and offshore. Customers are found in the marine paint industry and among other players in the shipping industry. I-Tech was founded in 2000 and has its headquarters in Mölndal.

Lue lisää
Markkina-arvo
755,86 milj. SEK
Vaihto
1 milj. SEK
Liikevaihto
EBIT %
P/E -luku
Osinkotuotto %
Liikevaihto ja EBIT-%

Liikevaihto milj.

EBIT-% (oik.)

EPS ja Osinko

EPS (oik.)

Osinko %

Pörssikalenteri
21.8.
2026

Osavuosikatsaus Q2'26

16.10.
2026

Osavuosikatsaus Q3'26

Kolmannen osapuolen analyysi

I-tech: 2026 looking better than feared - ABG

* Q1: Organic growth of +7% despite tough comps (vs. ABGSCe -15%) * Customer with financial constraints back to normal order cadence * We raise organic growth ests. for '26e to +25% (+15% previously) Q1 results Q1 sales were much stronger than we expected...

Liity Inderesin yhteisöön

Älä jää mistään paitsi – luo käyttäjätunnus ja ota kaikki hyödyt irti Inderesin palvelusta.

FREE-tili
Pörssin suosituin aamukatsaus
Analyytikon kommentit ja suositukset
Osakevertailu
PREMIUM-tili
Kaikki yhtiöraportit ja sisällöt
Premium-työkalut (mm. sisäpiirin kaupat ja screeneri)
Mallisalkku
Luo ilmainen tunnus
Kolmannen osapuolen analyysi

I-tech: Significant beat across the PL - ABG

* Sales +27% vs. ABGSCe, EBIT SEK 19m vs. ABGSCe 9.8m * A beat on all line items, despite very tough comps * Gross margin 60% (56% LY), though may soften on raw material prices Much stronger growth than expected Sales came in above expectations at SEK...

Kolmannen osapuolen analyysi

I-tech: Announce extension of Selektope until Dec '26 - ABG

* Approval for Selektope extended again, now until Dec '26 * Ongoing process could not be finalised within timeframe * I-Tech views this as positive; invests in new EOGRT study Approval extended again, until Dec '26 The European Commission and the Standing...

Kolmannen osapuolen analyysi

I-tech: Another growth breather in Q1e - ABG

* Q1e sales 42m (57m), adj. EBIT SEK 9.8m (18m) * Updated FX forecasts, we raise '26e-'28e sales by 4-5% * Trading at '26e-'28e EV/EBIT of 8x-3x Q1 expectations We estimate sales of SEK 42m (57m), -27% y-o-y (-15%% org., -12% FX). I-Tech is facing tough...

Kolmannen osapuolen analyysi

I-tech: A pause in pace, not the story - ABG

* Q4: -23% organic growth (vs. ABGSCe -12%) * Financially constrained customer weighed on ’25 org. growth * Long-term potential intact, expect continued CMP growth in '26e 2025, a mixed financial year Q4 organic growth came in below our estimate at -...

Kolmannen osapuolen analyysi

I-tech: Customer pullback weighing on growth - ABG

Sales -13% vs. ABGSCe, EBIT SEK 7.6m vs. ABGSCe 9.4m * Three coating products launched in Korea in Q4 * Sizeable customer with financial constraints impacting volumes Q4 results I-Tech reported sales of SEK 39m, falling 13% short of our estimate (-33...

Kolmannen osapuolen analyysi

I-tech: No easy lap into Q4e - ABG

* Q4e sales SEK 45m (58m), adj. EBIT SEK 10m (19m) * We cut '26e-'27e sales and EBIT by 10% and 22-19%, respectively * Lowered growth assumptions for CMP Tough comps in Q4e We estimate Q4 sales of SEK 45m, -23% y-o-y (-12% organic, -11% FX). I-Tech is...

Kolmannen osapuolen analyysi

I-tech: Proposed non-renewal of Selektope in the EU - ABG

* European Commission drafts proposal for non-renewal of Selektope* Limited impact on near-term estimates, EU ~2% of total sales* Voting expected to occur some time in H1'26, final decision in mid-26European Commission drafts proposal for non-renewal...